10,000 Patient Study in North America
100,000+ Tests Performed in the U.S.
Finds Right & Left Sided Cancers
Detects Colorectal Cancer & Precancerous Lesions (Stage 1 & 2)

ColonSentry® is a proprietary liquid biopsy test that uses advanced gene expression (mRNA) technology for the early identification of Colorectal Cancer (CRC). ColonSentry, was the first liquid biopsy for CRC, using our patented Sentinel Principle Technology Platform.

Following a ColonSentry test result, if the score is elevated in a patient at average risk, there is an increased probability the patient may have a pre-cancerous lesion or colorectal cancer. Studies have shown 80-95% of patients who refuse Colonoscopy will comply with a blood test. Patients are then 2 times more likely to comply with Colonoscopy. ColonSentry, in advance of Colonoscopy finds 2.1 to 4.7 times more CRC lesions. ColonSentry can reduce healthcare costs by more than 20% through early interventions.